These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 27614369)

  • 1. Euglycemic diabetic ketoacidosis in type 2 diabetes with sodium glucose cotransporter 2 inhibitors.
    Wang AY; Hou SK; Li SJ; Kao WF
    Am J Emerg Med; 2017 Feb; 35(2):379.e5-379.e6. PubMed ID: 27614369
    [No Abstract]   [Full Text] [Related]  

  • 2. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
    Bloomgarden ZT
    J Diabetes; 2016 Mar; 8(2):175-6. PubMed ID: 26611882
    [No Abstract]   [Full Text] [Related]  

  • 3. [Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].
    Zechmann S
    Praxis (Bern 1994); 2016 Mar; 105(6):349-50. PubMed ID: 26980688
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility.
    Cherney DZ; Udell JA
    Circulation; 2016 Dec; 134(24):1915-1917. PubMed ID: 27956401
    [No Abstract]   [Full Text] [Related]  

  • 5. Dapagliflozin-Associated Diabetic Ketoacidosis.
    Chakinala RC; Chang AP; Solanki S; Haq KF; Cho R
    Am J Ther; 2018; 25(6):e765-e766. PubMed ID: 29672334
    [No Abstract]   [Full Text] [Related]  

  • 6. [Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors].
    Valek R; Von der Mark J
    Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):145-148. PubMed ID: 27221094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes Drug Receives New Indication.
    Aschenbrenner DS
    Am J Nurs; 2017 Apr; 117(4):24-25. PubMed ID: 28333738
    [No Abstract]   [Full Text] [Related]  

  • 8. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
    Vettor R; Inzucchi SE; Fioretto P
    Diabetologia; 2017 Mar; 60(3):395-398. PubMed ID: 28074254
    [No Abstract]   [Full Text] [Related]  

  • 9. Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin.
    Rashid O; Farooq S; Kiran Z; Islam N
    BMJ Case Rep; 2016 May; 2016():. PubMed ID: 27177938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis.
    Rajasekeran H; Lytvyn Y; Cherney DZ
    Kidney Int; 2016 Mar; 89(3):524-6. PubMed ID: 26880444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology.
    Pfützner A; Klonoff D; Heinemann L; Ejskjaer N; Pickup J
    Endocrine; 2017 Apr; 56(1):212-216. PubMed ID: 28303514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 inhibitors and renal function.
    Med Lett Drugs Ther; 2016 Jul; 58(1499):91-2. PubMed ID: 27403782
    [No Abstract]   [Full Text] [Related]  

  • 13. [Life-threatening ketoacidosis in a 25-year-old woman treated with sodium-glucose cotransporter 2 inhibitor].
    Lindberg MJ; Kristensen FB; Yildiz A
    Ugeskr Laeger; 2016 Nov; 178(47):. PubMed ID: 27908315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
    Peters AL; Buschur EO; Buse JB; Cohan P; Diner JC; Hirsch IB
    Diabetes Care; 2015 Sep; 38(9):1687-93. PubMed ID: 26078479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
    Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
    Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly.
    Quarella M; Walser D; Brändle M; Fournier JY; Bilz S
    J Clin Endocrinol Metab; 2017 May; 102(5):1451-1453. PubMed ID: 28323955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment.
    Storgaard H; Bagger JI; Knop FK; Vilsbøll T; Rungby J
    Basic Clin Pharmacol Toxicol; 2016 Feb; 118(2):168-70. PubMed ID: 26291182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin-Associated Euglycemic Diabtetic Ketoacidosis.
    Soni P; Kumar V; Saradna A; Kupfer Y
    Am J Ther; 2018; 25(6):e740-e741. PubMed ID: 29746292
    [No Abstract]   [Full Text] [Related]  

  • 19. Empagliflozin for the treatment of Type 2 diabetes.
    Gangadharan Komala M; Mather A
    Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
    Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
    Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.